ArticleEuropean journal of medical research2026
SENP6-mediated desumoylation of SMAD5 regulates osteogenic fate in periodontal ligament stem cells.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPeriodontal ligament stem cells (PDLSCs) are essential for periodontal tissue regeneration, but their osteogenic differentiation is significantly impaired in the inflammatory microenvironment of periodontitis. This study aimed to investigate the regulatory role of the SENP6-SMAD5-SOX2 axis in PDLSC osteogenesis.
methodsTranscriptomic analysis of public datasets was used to identify key regulators. In vitro functional experiments, including siRNA-mediated knockdown, co-immunoprecipitation, and luciferase assays, were performed on PDLSCs isolated from healthy donors. The expression of SOX2 and early osteogenic markers (ALP and RUNX2) was assessed at day 7 of osteogenic induction. In vivo, the SENP6 inhibitor NSC632839 was evaluated in an LPS-induced mouse calvarial osteolysis model via micro-CT and H&E histological assessment.
resultsIn periodontitis tissues, SMAD5 protein was downregulated despite mRNA upregulation. In healthy PDLSCs, SENP6 knockdown stabilized SMAD5 protein and significantly upregulated the expression of SOX2 and early osteogenic markers ALP and RUNX2. Mechanistically, SMAD5 directly activated SOX2 transcription. In the mouse calvarial model, NSC632839 treatment effectively promoted bone formation and increased the bone volume fraction (BV/TV) through SOX2 upregulation, while the SMAD5 inhibitor CDD1653 exacerbated bone loss.
conclusionsThe SENP6-SMAD5-SOX2 axis is a critical regulator of early PDLSC osteogenic commitment. Pharmacological inhibition of SENP6 offers a promising therapeutic strategy for restoring bone regeneration in inflammatory environments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.